



LONGEVITY NEWSFLASH

June 2026



About this Bulletin

Welcome to the Newsflash , your monthly signpost to emerging research.

This complimentary digest highlights newly published peer-reviewed studies and key updates from public health and statistical agencies in the UK, US, and Canada, all selected for their relevance to the insurance and longevity sectors.

Rather than providing in-depth analysis, Newsflash is designed to guide you quickly and efficiently to valuable new material beyond the scope of our main bulletins, helping you stay informed and ahead of the curve.

Nicky Draper
Director of Life and
Health Consulting



Contents Table

- Journal Updates
 - Longevity and Mortality
 - Lifestyle
 - Endocrinology
 - Mental Health
 - Neurology
 - Oncology
 - Environment
- Other Health Bodies
 - Infectious Disease

Newsletter Highlights

Journal updates - Highlights

Smoking-attributable urological cancer deaths and DALYs rose globally from 1990 to 2021 despite falling age-standardised rates, with future absolute burden projected to keep rising to 2045 as populations age.

Journal Updates

Longevity and Mortality



Trends and Disparities in U.S. Mortality Rates Including COVID-19: An Analysis Using NCHS VSRR Provisional Estimates (2022-2024)

Alshargi 2026

J Community Health Nurs. 2026 JulSep;43(3):243-251

Analysis of NCHS provisional mortality data describing recent US mortality trends, sex differences and geographic variation from 2022 to 2024, including the continuing influence of COVID-19 and post-pandemic disruption.

10.1080/07370016.2026.2636641



Longevity and
Mortality

Mortality



Global, Regional, and National Age-Sex-Specific Burden of Alcohol-Related Diseases, 1990-2021: A Comprehensive Analysis for the Global Burden of Disease Study 2021

Liang 2026

J Stud Alcohol Drugs. 2026 Jul;87(4):642-654

GBD 2021 analysis mapping age-, sex- and region-specific trends in alcohol-related disease burden from 1990 to 2021, with particular attention to shifts around the COVID-19 period.

10.15288/jsad.25-00259.



Longevity and
Mortality

Mortality



Chronotype and All-Cause Mortality in US Middle-Aged and Older Adults: Results From the NHANES

Lin 2026

J Sleep Res. 2026 Aug;35(4):e70328.

Actigraphy-based NHANES analysis examining whether behavioural chronotype, estimated from weekend time-in-bed midpoint, is associated with all-cause mortality in US adults aged 50 and over.

10.1111/jsr.70328.



Longevity and
Mortality

Aging



Journal Updates

Lifestyle 

Trends in multimorbidity among US adults and the correlation between physical activity and mortality: Prospective cohort study from 1999 to 2018

Yu 2026**Medicine (Baltimore). 2026 Jul 3;105(27):e49564**

NHANES prospective cohort analysis examining trends in multimorbidity prevalence among US adults from 1999 to 2018 and the relationship between physical activity, mortality and life expectancy.

10.1097/MD.00000000000049564**Lifestyle**

Physical activity

Journal Updates

Endocrinology 



Prevalence, incidence, mortality, and years of life lost to diabetes from 1996 to 2024 in Denmark

Wibaek 2026

BMJ Open Diabetes Res Care. 2026 Jul 10;14(4):e006129

Nationwide Danish register-based cohort analysis estimating long-term trends in type 1 and type 2 diabetes prevalence, incidence, mortality and years of life lost from 1996 to 2024.

[10.1136/bmjdr-2026-006129](https://doi.org/10.1136/bmjdr-2026-006129)



Endocrinology

Diabetes



Journal Updates

Mental Health



Time Trends in Excess Mortality Among Individuals With Bipolar Disorder in Finland, 2000-2023: A Nationwide Register Study

Rimmington 2026

Bipolar Disord. 2026 Aug;28(5):e70147.

Nationwide Finnish register analysis tracking changes in all-cause mortality among people with bipolar disorder from 2000 to 2023, compared with the general population by age and sex.

10.1111/bdi.70147



Mental health

Bipolar



Journal Updates

Neurology

Diverging trends in motor neuron disease burden in China: an ageing-driven increase despite declining age-standardised rates - a GBD 2021 analysis

Ji 2026**Neurol Sci. 2026 Jul 3;47(8):604.**

GBD 2021 analysis examining how population ageing, population growth and age-specific rates have shaped trends in motor neuron disease burden in China from 1990 to 2021.

10.1007/s10072-026-09200-3**Neurology**

Motor neurone disease

Journal Updates

Oncology 



A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045

Chen 2026

Sci Prog. 2026 Jul-Sep;109(3):368504261466968

GBD 2021 analysis estimating global, regional and national burden of smoking-attributable prostate, bladder and kidney cancers among adults aged 40 and over, with projections to 2045.

10.1177/00368504261466968



Oncology

Prostate, bladder, and kidney cancer

Journal Updates

Environment 



Temporal dynamics of mortality risk from short-term air pollution exposure in Canada: An epidemiological analysis using time-varying non-linear models

Pan 2026

Environ Res. 2026 Sep 1;305(Pt 1):124938

Canadian census-division analysis using time-varying non-linear models to examine how short-term air pollution exposure relates to cause-specific mortality over time and by population size.

[10.1016/j.envres.2026.124938](https://doi.org/10.1016/j.envres.2026.124938)




Environment

Pollution

Other Health Bodies

Infectious Disease



Nearly 400 antibiotic-resistant infections each week in 2024

National surveillance data published by the UK Health Security Agency (UKHSA) show that the total number of antibiotic-resistant infections in 2024 equates to an average of nearly 400 newly reported cases per week.

<https://www.gov.uk/government/news/nearly-400-antibiotic-resistant-infections-each-week-in-2024>



**Infectious
disease**

Antibiotic resistant infections



UKHSA publishes first Health Security Risk Assessment in boost to pandemic preparedness

UKHSA publishes its first Health Security Risk Assessment (HSRA), which characterises the most significant health security risks facing the UK over the next 5 years.

<https://www.gov.uk/government/news/ukhsa-publishes-first-health-security-risk-assessment-in-boost-to-pandemic-preparedness>



**Infectious
disease**

Infectious disease

Our Ethos

At Crystallise we seek to clarify decision-making from biomedical evidence. Whether you are a pharmaceutical executive, healthcare manager or an actuary, we deliver high quality, competitively priced biomedical evidence syntheses, analyses and models – quickly, reliably and efficiently.

Our Vision

Crystallising medical evidence to improve decision making.

Our Mission

To make the synthesis and analysis of biomedical evidence more efficient, objective and reliable.

Our Values

Inclusiveness

Social responsibility

Innovation

Integrity

Reliability

Our Ethical Principles

Integrity

Social and Public Good
Consideration

Avoiding Conflicts of Interest

Probity

Honesty

Scientific and Methodological
Rigour

Transparency and Disclosure


Respect for Privacy and
Confidentiality

Accountability and Professionalism

Justice

Environmental Responsibility

Commitment to Continuous Ethical
Reflection



Disclaimer:

No data analysis was performed in the studies included in this newsletter.

For further information, please subscribe to Longevity Perspectives by contacting Nicky Draper (nicky.draper@crystallise.com).

For further information about Longevity Newsflash contact newsletter@crystallise.com

To speak to us about our services contact contact@crystallise.com

Registered address:
1 The Atrium, Phoenix Square
Wyncolls Road
Colchester
Essex CO4 9AS

Company No: 7980921
Data Protection Act Registration Number:
Z3363643